168 related articles for article (PubMed ID: 36226464)
1. Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing-off of erenumab within monthly treatment cycle.
Dodick DW; Blumenfeld AM; Halker Singh RB; Williams R; Zhang F; Chen PW; Hsu CP; Peng C; Snellman J; Chehrenama M; Ailani J
Headache; 2023 Feb; 63(2):233-242. PubMed ID: 36226464
[TBL] [Abstract][Full Text] [Related]
2. Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies.
Lipton RB; Dodick DW; Kudrow D; Reuter U; Tenenbaum N; Zhang F; Lima GPDS; Chou DE; Mikol DD
Cephalalgia; 2021 Dec; 41(14):1458-1466. PubMed ID: 34407654
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of erenumab in women with a history of menstrual migraine.
Pavlovic JM; Paemeleire K; Göbel H; Bonner J; Rapoport A; Kagan R; Zhang F; Picard H; Mikol DD
J Headache Pain; 2020 Aug; 21(1):95. PubMed ID: 32746775
[TBL] [Abstract][Full Text] [Related]
5. Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
Takeshima T; Sakai F; Hirata K; Imai N; Matsumori Y; Yoshida R; Peng C; Cheng S; Mikol DD
Headache; 2021 Jun; 61(6):927-935. PubMed ID: 34153117
[TBL] [Abstract][Full Text] [Related]
6. Does "wearing off" of efficacy occur in galcanezumab-treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials.
Ailani J; Kuruppu DK; Rettiganti M; Oakes T; Schroeder K; Wietecha L; Port M; Blumenfeld AM
Headache; 2022 Feb; 62(2):198-207. PubMed ID: 35076090
[TBL] [Abstract][Full Text] [Related]
7. No wearing-off effect of erenumab or fremanezumab for chronic migraine prevention: a single-center, real-world, observational study.
Florescu AM; Lannov LV; Younis S; Cullum CK; Chaudhry BA; Do TP; Amin FM
Cephalalgia; 2024 Jan; 44(1):3331024231222915. PubMed ID: 38215232
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.
Goadsby PJ; Paemeleire K; Broessner G; Brandes J; Klatt J; Zhang F; Picard H; Lenz R; Mikol DD
Cephalalgia; 2019 Jun; 39(7):817-826. PubMed ID: 30982348
[TBL] [Abstract][Full Text] [Related]
9. Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double-blind, placebo-controlled studies.
Hirata K; Takeshima T; Sakai F; Imai N; Matsumori Y; Tatsuoka Y; Numachi Y; Yoshida R; Peng C; Mikol DD; Lima GPDS; Cheng S
Brain Behav; 2022 Mar; 12(3):e2526. PubMed ID: 35201674
[TBL] [Abstract][Full Text] [Related]
10. Timing and durability of response to erenumab in patients with episodic migraine.
McAllister PJ; Turner I; Reuter U; Wang A; Scanlon J; Klatt J; Chou DE; Paiva da Silva Lima G
Headache; 2021 Nov; 61(10):1553-1561. PubMed ID: 34841526
[TBL] [Abstract][Full Text] [Related]
11. A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults.
Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Lenz R; Wang Y; Cheng S; Hirama T; Mikol DD
Headache; 2019 Nov; 59(10):1731-1742. PubMed ID: 31612482
[TBL] [Abstract][Full Text] [Related]
12. Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials.
Tepper SJ; Ashina M; Reuter U; Hallström Y; Broessner G; Bonner JH; Picard H; Cheng S; Chou DE; Zhang F; Klatt J; Mikol DD
J Headache Pain; 2021 Jul; 22(1):81. PubMed ID: 34301173
[TBL] [Abstract][Full Text] [Related]
13. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis.
Tepper SJ; Lipton RB; Silberstein SD; Kudrow D; Ashina M; Reuter U; Dodick DW; Wang A; Cheng S; Klatt J; Mikol DD
Headache; 2023 Jun; 63(6):730-742. PubMed ID: 37313616
[TBL] [Abstract][Full Text] [Related]
15. Erenumab for episodic migraine.
Datta A; Gupta S; Maryala S; Aggarwal V; Chopra P; Jain S
Pain Manag; 2022 Jul; 12(5):587-594. PubMed ID: 35313740
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.
Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Cheng S; Numachi Y; Peng C; Xue F; Mikol DD
Headache; 2021 Apr; 61(4):653-661. PubMed ID: 33764538
[TBL] [Abstract][Full Text] [Related]
17. One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study.
Goadsby PJ; Reuter U; Hallström Y; Broessner G; Bonner JH; Zhang F; Wright IK; Chou DE; Klatt J; Picard H; Lenz RA; Mikol DD
Neurology; 2020 Aug; 95(5):e469-e479. PubMed ID: 32636324
[TBL] [Abstract][Full Text] [Related]
18. Timing and durability of response to erenumab in patients with chronic migraine.
Tepper SJ; Lucas S; Ashina M; Schwedt TJ; Ailani J; Scanlon J; Klatt J; Chou DE; Wang A; Paiva da Silva Lima G
Headache; 2021 Sep; 61(8):1255-1263. PubMed ID: 34363708
[TBL] [Abstract][Full Text] [Related]
19. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial.
Tepper SJ; Diener HC; Ashina M; Brandes JL; Friedman DI; Reuter U; Cheng S; Nilsen J; Leonardi DK; Lenz RA; Mikol DD
Neurology; 2019 May; 92(20):e2309-e2320. PubMed ID: 30996056
[TBL] [Abstract][Full Text] [Related]
20. Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study.
Diener HC; Ashina M; Ritter S; Paiva Da Silva Lima G; Rasmussen S; Zielman R; Tfelt-Hansen P
Cephalalgia; 2021 Oct; 41(11-12):1262-1267. PubMed ID: 33939497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
